申请人:EISAI R&D MANAGEMENT CO., LTD.
公开号:US20150105370A1
公开(公告)日:2015-04-16
Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
该公开的实施例涉及选择性替代喹啉化合物,其作为Toll样受体7和/或8的拮抗剂或抑制剂,并其在制药组合物中的使用,用于治疗系统性红斑狼疮(SLE)和狼疮性肾炎。